- Home
- MRSN
as 09-17-2025 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 37.0M | IPO Year: | 2017 |
| Target Price: | $33.00 | AVG Volume (30 days): | 62.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.21 - $70.75 | Next Earning Date: | 11-12-2025 |
| Revenue: | $34,769,000 | Revenue Growth: | 16.14% |
| Revenue Growth (this year): | -36.29% | Revenue Growth (next year): | -22.12% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Huber Martin H. Jr. | MRSN | President, CEO | Sep 12 '25 | Sell | $7.31 | 2,012 | $14,707.72 | 9,572 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
GlobeNewswire
3 months ago
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
GlobeNewswire
4 months ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
MT Newswires
4 months ago
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating
GuruFocus.com
4 months ago
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...
Thomson Reuters StreetEvents
4 months ago
Q1 2025 Mersana Therapeutics Inc Earnings Call
GlobeNewswire
4 months ago
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
Zacks
4 months ago
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.